摘要
目的观察分析芪凌方联合表阿霉素膀胱灌注化疗对浅表性膀胱癌经尿道膀胱肿瘤切除术患者术后复发的预防作用。方法选取2018年7月—2019年12月在上海中医药大学附属龙华医院住院的浅表性膀胱癌术后患者178例,将其分为观察组与对照组,每组患者89例,对照组采用表阿霉素40 mg膀胱内灌注化疗,1次/周,治疗为期8周;8周后改为1次/月,治疗为期1年;观察组在对照组治疗基础上加用口服"周氏芪凌方",1剂/天,治疗为期3个月。随访观察2年,比较2组患者术后复发情况和总健康情况评分。结果观察组和对照组术后1年复发率分别为5.62%和12.36%,2年复发率分别为11.24%和17.98%。观察组明显低于对照组(P<0.05);TURBt术后6个月,总健康情况评分观察组(52.2±4.6)分,对照组(65.7±6.7)分,两组评分较治疗前有明显改善(P<0.05),且观察组与对照组对比改善更为明显(P<0.05)。肿瘤复发和进展相关变量分析显示,联合应用芪凌方与复发率降低(HR=0.165,95%CI 0.069~0.397,P=0.000)和进展率降低(HR=0.160,95%CI 0.032~0.799,P=0.026)显著相关。结论芪凌方联合表阿霉素膀胱内灌注化疗降低了浅表性膀胱癌的术后2年内的复发几率,对患者的生命质量和总健康情况也起到了一定的改善。
Objective To observe and analyze the preventive effects of Qiling formulations combined with epirubicin injection chemotherapy to patients with superficial bladder cancer after resection of transurethral cystectomy.Methods We selected 178 patients with superficial bladder cancer in our hospital from July 2018 to December. The observation group was given a "Qiling of Zhou" recipe. Basis for treatment of control groups. 1 dose/day, treatment period is 3 months. Two years follow-up was performed to compare the recurrence and total health score of the two groups.Results The results of the first and second groups were 5.62% and 12.36%, respectively. The observation group was significantly lower than the control group(P<0.05). Six months after TURBT, the total health score of the observation group was(52.2±4.6) points, and the control group was(65.7±6.7) points. The two score groups were significantly improved compared to those before treatment(P<0.05), and(65.7±6.7) points in the observation group were significantly improved compared to(52.2±4.6) points in the control group(P<0.05). The analysis of the variables associated with the recurrence and progression of the tumor significantly correlated with the reduction of recurrence rate(HR=0.165, 95% CI 0.069 to 0.397, P=0.000) and the rate of progress(HR=0.160, 95%CI 0.032 to 0.799, P=0.026).Conclusion Qiling prescriptions combined with epirubicin intravascular infusion reduce the rate of recurrence of superficial bladder cancer within two years after surgery and improve the quality of life and general health of patients.
作者
孙鹏
陈磊
曹宏文
高人杰
冯懿赓
周智恒
SUN Peng;CHEN Lei;CAO Hong-wen;GAO Ren-jie;FENG Xi-geng;ZHOU Zhi-heng(Longhua Hospital Shanghai University of Tradilional Chinese Medicine,Shanghai 200032,China)
出处
《医药论坛杂志》
2021年第7期58-61,65,共5页
Journal of Medical Forum
基金
上海市科学技术委员会科研计划项目(19ZR1458200)。
关键词
浅表性膀胱癌
周氏芪凌方
表阿霉素
膀胱内灌注化疗
Superficial bladder cancer
Peripheral Qiling prescription
Epirubicin
Bladder chemotherapy
